Suppression of basophil activation by IgE glycovariants
IgE 糖变体抑制嗜碱性粒细胞活化
基本信息
- 批准号:9900056
- 负责人:
- 金额:$ 33.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-15 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAffinityAllergensAllergicAllergic DiseaseAllergic ReactionAnaphylaxisAnimal ModelAntibodiesBasophilsBindingCarbohydratesCell Culture TechniquesCell LineCell Surface ReceptorsCellsChronicComplexDataEffector CellEngineeringExtrinsic asthmaFamilyHumanHypersensitivityITIMIgEIgE ReceptorsImmune systemImmunologyIn VitroIncidenceInflammatoryInflammatory ResponseLaboratoriesLigationLinkLocationMediatingModificationMoldsMolecularMusPathway interactionsPatientsPlayPollenPolysaccharidesRoleRouteSignal TransductionSiteStructureSurfaceTestingTherapeutic antibodiesTransgenic MiceUrticariaVariantallergic responsebasecarbohydrate structuredanderdesignglycosylationin vivoinhibitor/antagonistinsightmast cellmembermutantnovelomalizumabpyroglyphidreceptorrecruitresponsesialic acid binding Ig-like lectinstructural biology
项目摘要
Project Summary
Most allergic reactions are caused by immunoglobulin E (IgE) antibodies that are specific for allergens and
trigger potent inflammatory responses mediated by mast cells and basophils. IgE binds to the high affinity
receptor (FcεRI) expressed on these allergic effector cells, making this a key interaction that is common to
many different allergen-specific responses. The anti-IgE therapeutic antibody (Omalizumab) is currently used
to treat allergic asthma and chronic idiopathic urticaria in patients. We determined the structure of the
Omalizumab Fab bound to the IgE-Fc, clarifying how Omalizumab blocks IgE interactions with both receptors.
We also designed an IgE-Fc glycosylation mutant that does not bind Omalizumab, but retains interactions with
high and low affinity IgE receptors. This IgE glycovariant can be co-administered with Omalizumab, to replace
the cell-bound IgE, exchanging allergen-reactive IgE with a non-reactive variant. This co-treatment of cells
provides synergistic inhibition that is more potent at blocking basophil activation than either inhibitor alone. Our
IgE glycovariant, which incorporates a single additional N-linked glycosylation site into the IgE-Fc, also shows
more potent inhibition of basophils on its own as compared to the wild type IgE-Fc. The inhibition does not
require direct competition for FceRI binding by “allergic” IgE. We hypothesize that carbohydrate-specific
inhibitory receptors, such as members of the Siglec family, may be engaged by the IgE glycovariant to block
FcεRI signaling. In this proposal, we will explore the impact of IgE glycosylation on the inhibition of human
basophil activation, both with and without concomitant Omalizumab treatment, and identify the mechanisms by
which IgE glycovariants suppress FceRI-dependent activation of allergic inflammatory cells.
项目摘要
大多数过敏反应是由免疫球蛋白E(IgE)抗体引起的,这种抗体是针对过敏原和
触发由肥大细胞和嗜碱性粒细胞介导的强烈炎症反应。免疫球蛋白与高亲和力结合
受体(FcεRI)在这些过敏效应细胞上表达,使这一关键相互作用普遍存在于
许多不同的过敏原特异性反应。目前使用的是抗IgE治疗性抗体(Omalizumab)
用于治疗过敏性哮喘和慢性特发性荨麻疹患者。我们确定了
Omalizumab Fab与IgE-Fc结合,阐明omalizumab如何阻止IgE与两种受体的相互作用。
我们还设计了一种IgE-Fc糖基化突变体,它不与奥马珠单抗结合,但保留了与
高、低亲和力的IgE受体。这种IgE糖变异体可以与奥马珠单抗联合使用,以取代
与细胞结合的IgE,与非反应性变异体交换过敏原反应性IgE。细胞的这种共处理
提供协同抑制,在阻止嗜碱性细胞激活方面比单独使用任何一种抑制剂都更有效。我们的
Ige糖变异体在IgE-Fc中加入了一个额外的N-连接糖基化位点,也显示出
与野生型IgE-Fc相比,其自身对嗜碱性粒细胞的抑制作用更强。这种抑制并不是
需要通过“过敏性”IgE直接竞争FceRI结合。我们假设碳水化合物专一性
抑制性受体,如Siglec家族的成员,可能被IgE糖变异体激活以阻断
FCεRI信令。在这项建议中,我们将探讨IgE糖基化对人血清白蛋白抑制的影响。
在奥马珠单抗治疗和不联合奥马珠单抗治疗的情况下,嗜碱性细胞的激活,并通过
哪些IgE糖变异体抑制FceRI依赖的变态反应性炎症细胞的激活。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Theodore S Jardetzky其他文献
Theodore S Jardetzky的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Theodore S Jardetzky', 18)}}的其他基金
Discovery and engineering of novel anti-IgE disruptive inhibitors
新型抗 IgE 破坏性抑制剂的发现和工程设计
- 批准号:
10353982 - 财政年份:2021
- 资助金额:
$ 33.02万 - 项目类别:
Discovery and engineering of novel anti-IgE disruptive inhibitors
新型抗 IgE 破坏性抑制剂的发现和工程设计
- 批准号:
10495213 - 财政年份:2021
- 资助金额:
$ 33.02万 - 项目类别:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
五聚体和三聚体复合物介导的人巨细胞病毒进入细胞
- 批准号:
10468251 - 财政年份:2020
- 资助金额:
$ 33.02万 - 项目类别:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
五聚体和三聚体复合物介导的人巨细胞病毒进入细胞
- 批准号:
10687819 - 财政年份:2020
- 资助金额:
$ 33.02万 - 项目类别:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
五聚体和三聚体复合物介导的人巨细胞病毒进入细胞
- 批准号:
10120270 - 财政年份:2020
- 资助金额:
$ 33.02万 - 项目类别:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
五聚体和三聚体复合物介导的人巨细胞病毒进入细胞
- 批准号:
10265549 - 财政年份:2020
- 资助金额:
$ 33.02万 - 项目类别:
Repertoire studies of human antibodies to RSV and MPV F
RSV 和 MPV F 人类抗体的谱研究
- 批准号:
10249184 - 财政年份:2018
- 资助金额:
$ 33.02万 - 项目类别:
Suppression of basophil activation by IgE glycovariants
IgE 糖变体抑制嗜碱性粒细胞活化
- 批准号:
10091046 - 财政年份:2018
- 资助金额:
$ 33.02万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Continuing Grant